Drugs / SAB-176
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06435936 | Apr 2024 → Feb 2025 overdue | pseudohypoparathyroidism type 1A | SAb Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04471038 | Jul 2020 → Apr 2021 | influenza | SAb Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04850898 | Jun → Oct 2021 | swine influenza | SAb Biotherapeutics, Inc. | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-09-15 | SAb Biotherapeutics, Inc. | SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza sab.bio ↗ |
| 2021-06-29 | SAb Biotherapeutics, Inc. | SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza sab.bio ↗ |
| 2020-07-30 | SAb Biotherapeutics, Inc. | SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza sab.bio ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAB-176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06435936 ↗ |
| Modality | Protein / enzyme biologic | “human immunoglobulin” NCT04471038 ↗ |
| Route | Intravenous | “intravenous therapeutic” NCT04471038 ↗ |